The aim of this study was to evaluate clinicopathological features, oncological outcome and prognostic factors for recurrence in advanced stage uterine serous carcinoma (USC) patients.
Patients with 2009 International Federation of Gynecology and Obstetrics stage III&IV uterine serous carcinoma were enrolled from 4 gynecologic oncology centers and a study group was created. Response to therapy was evaluated according to the WHO criteria. Progression-free survival (PFS) and overall survival (OS) estimates were determinated by using the Kaplan-Meier method. Survival curves were compared with the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.
Entire cohort included 63 patients. Median age of cohort was 64 years. Thirty-five (55.6%) patients were stage IV. Lymphadenectomy was performed in 57 (90.5%) patients and lymph node metastasis was positive in 45 (71.4%) patients. Maximal cytoreduction (no residue tumor) was achieved in 53 (84.1%) patients. However, optimal cytoreduction (residue tumor ≤1 cm) was achieved in 6 (9.5%) patients and suboptimal cytoreduction (residue tumor >1 cm) was achieved in 3 (4.8%) patients. Median follow-up time was 19 (range;1-152) months. Complete clinical response was obtained in 58 (92.1%) patients after standard adjuvant therapy. Disease failure was detected in 25 patients. Study group had a 2-year PFS of 51% and 2-year OS of 80%. On multivariate analysis, performing lymphadenectomy was an independent prognostic factor for PFS (Odds ratio: 24.794, 95% Confidence Interval: 4.214-145.869; p < 0.001).
Lymphadenectomy should be a part of the standard surgical therapy in advanced stage USC.Le texte complet de cet article est disponible en PDF.
Keywords : Advanced stage, lymphadenectomy, uterine serous carcinoma, survival